Products Lenvatinib
Lenvatinib Phase 2 Completed ⚡ Active Relapsed or Refractory Solid Tumors
Relapsed or Refractory Solid Tumors
Jul 30, 2020 → Feb 13, 2025
About Lenvatinib Lenvatinib is a phase 2 stage product being developed by Eisai for Relapsed or Refractory Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT04447755. Target conditions include Relapsed or Refractory Solid Tumors.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT03533361 Pre-clinical Completed — — Thyroid Cancer NCT02211222 Pre-clinical Completed — Jun 1, 2015 Differentiated Thyroid Cancer NCT05901194 Phase 1/2 Active Jul 10, 2024 Apr 1, 2027 Hepatocellular Carcinoma Non-resectable NCT06138769 Phase 2 Active Jul 20, 2023 Nov 1, 2027 Hepatocellular Carcinoma NCT05171335 Phase 2 Recruiting Jun 20, 2022 Dec 30, 2027 Hepatocellular Carcinoma NCT05103904 Phase 2 Recruiting Apr 19, 2022 Nov 4, 2026 Recurrent Hepatocellular Carcinoma NCT04321954 Phase 2 Active Mar 9, 2021 May 27, 2026 Differentiated Thyroid Cancer NCT04297254 Approved Completed Feb 4, 2021 Jul 31, 2023 Carcinoma, Hepatocellular NCT04447755 Phase 2 Completed Jul 30, 2020 Feb 13, 2025 Relapsed or Refractory Solid Tumors NCT04008082 Pre-clinical Completed May 14, 2019 Jan 28, 2022 Carcinoma, Hepatocellular NCT03506048 Phase 2 Terminated Jan 16, 2019 Jun 24, 2021 Differentiated Thyroid Gland Carcinoma NCT03009292 Phase 1 Completed Aug 6, 2018 Aug 27, 2021 Solid Tumor NCT03663114 Pre-clinical Completed Jul 2, 2018 Feb 20, 2020 Carcinoma, Hepatocellular NCT02846766 Phase 2 Withdrawn Jul 1, 2018 Jun 1, 2021 Cancer NCT03433703 Phase 2 Terminated Apr 26, 2018 Jan 7, 2019 Carcinoma, Hepatocellular NCT03573960 Approved Completed Apr 1, 2018 Sep 4, 2025 Thyroid Neoplasms NCT03168074 Phase 2 UNKNOWN Mar 28, 2017 Mar 28, 2021 Breast Cancer NCT02953743 Phase 1 Completed Sep 1, 2016 Dec 28, 2020 Unresectable Hepatocellular Carcinoma (HCC) NCT02780310 Phase 2 Active May 19, 2016 May 1, 2026 Adenoid Cystic Carcinoma NCT02579616 Phase 2 Completed Oct 23, 2015 Feb 27, 2019 Biliary Tract Cancer
Competing Products 20 competing products in Relapsed or Refractory Solid Tumors
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3 Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab Eli Lilly Phase 1/2
Other Products from Eisai